Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma
NCT04730232Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Dec 2020
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in urothelial carcinoma (UC), sponsored by The Second Hospital of Tianjin Medical University. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04730232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730232.